These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 22433961)

  • 21. Human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine: immunogenicity and safety in healthy Chinese women from Hong Kong.
    Ngan HY; Cheung AN; Tam KF; Chan KK; Tang HW; Bi D; Descamps D; Bock HL
    Hong Kong Med J; 2010 Jun; 16(3):171-9. PubMed ID: 20519752
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy, Immunogenicity, and Safety of a 9-Valent Human Papillomavirus Vaccine: Subgroup Analysis of Participants From Asian Countries.
    Garland SM; Pitisuttithum P; Ngan HYS; Cho CH; Lee CY; Chen CA; Yang YC; Chu TY; Twu NF; Samakoses R; Takeuchi Y; Cheung TH; Kim SC; Huang LM; Kim BG; Kim YT; Kim KH; Song YS; Lalwani S; Kang JH; Sakamoto M; Ryu HS; Bhatla N; Yoshikawa H; Ellison MC; Han SR; Moeller E; Murata S; Ritter M; Sawata M; Shields C; Walia A; Perez G; Luxembourg A
    J Infect Dis; 2018 Jun; 218(1):95-108. PubMed ID: 29767739
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine.
    Giuliano AR; Lazcano-Ponce E; Villa L; Nolan T; Marchant C; Radley D; Golm G; McCarroll K; Yu J; Esser MT; Vuocolo SC; Barr E
    J Infect Dis; 2007 Oct; 196(8):1153-62. PubMed ID: 17955433
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine.
    Ault KA; Giuliano AR; Edwards RP; Tamms G; Kim LL; Smith JF; Jansen KU; Allende M; Taddeo FJ; Skulsky D; Barr E
    Vaccine; 2004 Aug; 22(23-24):3004-7. PubMed ID: 15297048
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women.
    Block SL; Nolan T; Sattler C; Barr E; Giacoletti KE; Marchant CD; Castellsagué X; Rusche SA; Lukac S; Bryan JT; Cavanaugh PF; Reisinger KS;
    Pediatrics; 2006 Nov; 118(5):2135-45. PubMed ID: 17079588
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quadrivalent human papillomavirus (HPV) types 6, 11, 16, 18 vaccine: for the prevention of genital warts in males.
    Garnock-Jones KP; Giuliano AR
    Drugs; 2011 Mar; 71(5):591-602. PubMed ID: 21443282
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Co-administration of human papillomavirus-16/18 AS04-adjuvanted vaccine with hepatitis B vaccine: randomized study in healthy girls.
    Schmeink CE; Bekkers RL; Josefsson A; Richardus JH; Berndtsson Blom K; David MP; Dobbelaere K; Descamps D
    Vaccine; 2011 Nov; 29(49):9276-83. PubMed ID: 21856349
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine.
    Villa LL
    Int J Infect Dis; 2007 Nov; 11 Suppl 2():S17-25. PubMed ID: 18162241
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long term follow up of persistence of immunity following quadrivalent Human Papillomavirus (HPV) vaccine in immunocompromised children.
    MacIntyre CR; Shaw PJ; Mackie FE; Boros C; Marshall H; Seale H; Kennedy SE; Moa A; Chughtai AA; Trent M; O'Loughlin EV; Stormon M
    Vaccine; 2019 Sep; 37(37):5630-5636. PubMed ID: 31402238
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.
    Garland SM; Hernandez-Avila M; Wheeler CM; Perez G; Harper DM; Leodolter S; Tang GW; Ferris DG; Steben M; Bryan J; Taddeo FJ; Railkar R; Esser MT; Sings HL; Nelson M; Boslego J; Sattler C; Barr E; Koutsky LA;
    N Engl J Med; 2007 May; 356(19):1928-43. PubMed ID: 17494926
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in Chinese females aged 9 to 26 years: A phase 3, open-label, immunobridging study.
    Huang Z; He J; Su J; Ou Z; Liu G; Fu R; Shou Q; Zheng M; Group T; Luxembourg A; Liao X; Zhang J
    Vaccine; 2021 Jan; 39(4):760-766. PubMed ID: 33239228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical Trial.
    Qiao YL; Wu T; Li RC; Hu YM; Wei LH; Li CG; Chen W; Huang SJ; Zhao FH; Li MQ; Pan QJ; Zhang X; Li Q; Hong Y; Zhao C; Zhang WH; Li YP; Chu K; Li M; Jiang YF; Li J; Zhao H; Lin ZJ; Cui XL; Liu WY; Li CH; Guo DP; Ke LD; Wu X; Tang J; Gao GQ; Li BY; Zhao B; Zheng FX; Dai CH; Guo M; Zhao J; Su YY; Wang JZ; Zhu FC; Li SW; Pan HR; Li YM; Zhang J; Xia NS
    J Natl Cancer Inst; 2020 Feb; 112(2):145-153. PubMed ID: 31086947
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Introducing human papillomavirus vaccines - questions remain.
    Paavonen J; Lehtinen M
    Ann Med; 2008; 40(3):162-6. PubMed ID: 18382882
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study.
    Mok CC; Ho LY; Fong LS; To CH
    Ann Rheum Dis; 2013 May; 72(5):659-64. PubMed ID: 22589375
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Human papillomavirus prophylactic vaccines: stakes and perspectives].
    Hantz S; Alain S; Denis F
    Gynecol Obstet Fertil; 2006; 34(7-8):647-55. PubMed ID: 16807045
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP).
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 May; 59(20):630-2. PubMed ID: 20508594
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gardasil 9--a broader HPV vaccine.
    Med Lett Drugs Ther; 2015 Mar; 57(1465):47-8. PubMed ID: 25853579
    [No Abstract]   [Full Text] [Related]  

  • 38. HPV vaccine and males: issues and challenges.
    Zimet GD; Rosenthal SL
    Gynecol Oncol; 2010 May; 117(2 Suppl):S26-31. PubMed ID: 20129653
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity of quadrivalent HPV vaccine among girls 11 to 13 Years of age vaccinated using alternative dosing schedules: results 29 to 32 months after third dose.
    Lamontagne DS; Thiem VD; Huong VM; Tang Y; Neuzil KM
    J Infect Dis; 2013 Oct; 208(8):1325-34. PubMed ID: 23901077
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevention strategies against human papillomavirus in males.
    Garland SM
    Gynecol Oncol; 2010 May; 117(2 Suppl):S20-5. PubMed ID: 20138347
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.